• Finch Therapeutics’ C. Difficile drug gets breakthrough status pharmaceutical-technology
    February 13, 2019
    Microbial therapies developer Finch Therapeutics has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for its investigational CP101 drug to treat recurrent Clostridium difficile (C. difficile) infection.....
PharmaSources Customer Service